Althea Group (ASX:AGH) - CEO, Joshua Fegan
CEO, Joshua Fegan
Source: Althea
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Australian pharmaceutical company Althea Group (AGH) has signed a supply and distribution agreement with Nimbus Health to sell its medicinal cannabis in Germany
  • Nimbus is a pharmaceutical wholesaler with approximately 25 per cent of the market share across medicinal cannabis sales in Germany
  • Under the three-year agreement, Nimbus will sell and distribute Althea’s medicinal cannabis range
  • The company is anticipating the first shipment of medicinal cannabis to arrive in Germany in the second half of this year
  • Althea is up 5.13 per cent on the market this morning, trading for 41¢ each

Australian pharmaceutical company Althea Group (AGH) has signed a supply and distribution agreement with Nimbus Health to sell its medicinal cannabis in Germany.

Nimbus is a pharmaceutical wholesaler with approximately 25 per cent of the market share across medicinal cannabis sales in Germany.

Althea is a supplier of medicinal cannabis. It also offers a range of education, access and management services to support eligible patients and healthcare professionals.

Under the three-year agreement, Nimbus will sell and distribute Althea’s full suite of medicinal cannabis, under Althea’s brand name in Germany. Althea will receive payment for products supplied by Nimbus, along with 50 per cent of the net profit sales.

The company is anticipating the first shipment of medicinal cannabis to arrive in Germany in the second half of this year.

“Althea believes that it is ideally positioned to become the market-leading medicinal cannabis brand in Germany,” the company said.

“With a population of 82.3 million and a favourable regulatory environment, German’s medicinal cannabis market is one of the largest in Europe,” it added.

Althea is up 5.13 per cent on the market this morning, trading for 41¢ each at 10:13 am AEST.

AGH by the numbers
More From The Market Herald

" Invex Therapeutics (ASX:IXC) receives FDA approval for third-phase Presendin clinical trial

Invex Therapeutics (ASX:IXC) has been given the tick of approval in the US for the development…
The Market Herald Video

" Mayne Pharma (ASX:MYX) CEO to retire following role relocation to the US

Mayne Pharma (ASX:MYX) CEO Scott Richards to retire following the company's decision to relocate the CEO…

" Emyria (ASX:EMD) receives positive screening results for MDMA-inspired analogues

Emyria (ASX:EMD) has received positive screening results from its MDMA novel drug discovery program with the…
The Market Herald Video

" Dimerix (ASX:DX8) closes recruitment for COVID-19 study early

Dimerix (ASX:DX8) has closed recruitment for its DMX-200 COVID-19 study, led by CLARITY 2.0, early so…